Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2012

View Archived Issues

EMERGE study results presented for pegylated interferon lambda-1a

Gene therapy rescues retinal degeneration in Prom1 knockout mice

Gene therapy shows promise for retinal degeneration

GlaxoSmithKline patents novel CRAC inhibitors

U.S. team develops new immunogenic polypeptides for HIV infection

Lupin synthesizes novel voltage-gated sodium channel blockers

Merck KGaA designs new MetAP 2 inhibitors

Presidio Pharmaceuticals discloses new compounds targeting NS5A protein

Biomarkers of inflammation are associated with AMD severity

S1 Biopharma expands focus

Early clinical data for ABT-267 monotherapy and combination treatment shows promise

Biovest plans to seek European marketing approval for cancer vaccine

New phase III Lu-AA-21004 data in MDD support planned regulatory filings

Bristol-Myers Squibb establishes first discovery collaboration in China

Newron completes phase III program for safinamide, signs new licensing agreement

Maxygen to receive payment from Bayer HealthCare for factor VIIa program

Resminostat enters clinical development in Japan

KineMed and CHDI Foundation enter biomarker collaboration

Livatag begins phase III trial for liver cancer

Fibrocell Science submits protocol to FDA for azficel-T study

Cyclacel gives update on phase II/III sapacitabine study

IDRI finds partner for tuberculosis vaccine candidate

Scil Proteins enters into collaboration with Ono Pharmaceutical

L-DOS-47 begins phase I/II study for NSCLC

Furiex enters into licensing agreements for Priligy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...